The combined entity after the merger of Pfizer#39;s off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.This week in Pharma: Potential Pfizer-Mylan deal could begin consolidation of generic industry
The combined entity after the merger of Pfizer#39;s off-patent business and Mylan would become the largest generic drug maker globally, and may set the pace for the consolidation of an industry facing pricing pressure amidst competition and channel consolidation in US market.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment